- ANGLE has announced that first research use sales of the Parsortix system have been secured in line with the strategy set out in the company's preliminary results on 23 July. The company estimates that the addressable market for research use sales for Parsortix is around £250 million per annum and ANGLE is seeking to achieve a gradual growth in revenues from this segment. Revenues are expected to be modest initially but to grow over time.

ANGLE is initially targeting sales to leading cancer research centres. In addition to revenue contribution, research use sales broaden the range of users of the system investigating new clinical applications in different cancer types and generating additional posters, publications and clinical evidence of the value of the Parsortix liquid biopsy.

Founder and chief executive Andrew Newland said: "Following strong third party evaluations of the Parsortix system and a successful and sustained phase of optimising the system's operation, efficiency and consistency, we believe ANGLE's Parsortix system is a market leading, robust and high performance CTC liquid biopsy solution. Customer interest is encouraging and we expect to see growing research use sales ahead of entering the clinical market."

At 9:38am: [LON:AGL] Angle PLC share price was 0p at 71.5p

Story provided by